Table 3.
Novel therapeutics suitable for repositioning for the seven diseases
| PH | Target | *Drug name | Status | Current Indication | Action | *Database |
|---|---|---|---|---|---|---|
| T1D | RARA | Alitretinoin | Approved | Kaposi's sarcoma | Agonist | TTD |
| GSK3B | Lithium | Unknown | Bipolar disorder | Unknown | PharmGKB | |
| T2D | CHRM1 | Pirenzepine | Approved | Peptic ulcer disease | Antagonist | TTD |
| LPL | Gemfibrozil | Approved | Hyperlipidemia | Activator | TTD | |
| CAD | FLT1 | Sorafenib | Launched | Advanced renal cell carcinoma | Inhibitor | TTD |
| KDR | Sunitinib | Launched | Advanced renal cell carcinoma | Inhibitor | TTD | |
| BD | ESR1 | Trilostane | Approved | Cushing's syndrome | aModulator | DrugBank |
| ABCC1 | Methotrexate | Unknown | Psoriasis | Unknown | PharmGKB | |
| HT | TACR1 | GSK1144814 | Phase I | Schizophrenia | Antagonist | TTD |
| NRP1 | Palifermin | Approved | Oral mucositis | Unknown | DrugBank | |
| CD | CRHR1 | CRF-1 antagonist | Phase II completed | Irritable bowel syndrome | Antagonist | TTD |
| INSR | Insulin Detemir | Approved | Type I and II Diabetes | Agonist | DrugBank | |
| RA | HLA - DRB 1 | Glatiramer Acetate | Approved | Multiple sclerosis | Binder | TTD |
| ACE | Ramipril | Approved | Hypertension | Inhibitor | DrugBank | |
Abbreviations - PH - Phenotypes; T2D - Type 2 Diabetes; T1D - Type 1 Diabetes; CAD - Coronary Artery Disease; BD - Bipolar Disorder; HT - Hypertension; CD - Crohn's Disease; RA - Rheumatoid Arthritis; TTD - Therapeutic Target Database; PharmGKB - Pharmacogenomics Knowledgebase.
Examples of novel therapeutics suitable for repositioning towards cure of seven diseases. (* Drugs mentioned in the table are only examples as one target may have multiple drugs); (* Drug databases in the table are only examples as one drug-target association may be present in more than one database); (a Allosteric Modulator).